Literature DB >> 8877100

Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression.

A Manni1, E Buckwalter, R Etindi, S Kunselman, A Rossini, D Mauger, D Dabbs, L Demers.   

Abstract

To address the isoenzyme-specific involvement of protein kinase C (PKC) in breast cancer biology, hormone-responsive MCF-7 breast cancer cells were infected with either PKC-alpha or -beta 1 cDNAs subcloned in the retroviral expression vector pMV7. Several stable clones of PKC-overexpressing cells were generated. Western analysis revealed cross-regulation between the alpha and beta isoforms, because induction of overexpression of one up-regulated the other. Overexpression of the alpha and beta isoenzymes, on the other hand, did not affect the already high endogenous expression of the novel delta, epsilon, eta, and zeta isoforms. Compared with control clones, PKC-alpha- and -beta-overexpressing MCF-7 cells exhibited more drastic morphological changes in response to phorbol 12-myristate 13-acetate administration characterized by cellular flattening and vacuolization. More importantly, induction of PKC-alpha and -beta overexpression induced a less aggressive biological behavior, which was characterized by reduced in vitro invasiveness and markedly diminished tumor formation and growth in nude mice. These in vivo findings can probably best be explained by the dramatic down-regulation of estrogen receptor levels observed in tumors derived from PKC-alpha-infected MCF-7 cells. Our data clearly show that it is possible to induce a less aggressive breast cancer phenotype by altering PKC isoenzyme expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877100

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  10 in total

Review 1.  Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis.

Authors:  E M Deacon; J Pongracz; G Griffiths; J M Lord
Journal:  Mol Pathol       Date:  1997-06

Review 2.  Classical Protein Kinase C: a novel kinase target in breast cancer.

Authors:  R K Singh; S Kumar; M S Tomar; P K Verma; S P Singh; P K Gautam; A Acharya
Journal:  Clin Transl Oncol       Date:  2018-07-30       Impact factor: 3.405

Review 3.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

Review 4.  Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity.

Authors:  L Hilakivi-Clarke; R Clarke
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

5.  Adhesion of renal carcinoma cells to endothelial cells depends on PKCmu.

Authors:  Walburgis Brenner; Silke Beitz; Elke Schneider; Frank Benzing; Ronald E Unger; Frederik C Roos; Joachim W Thüroff; Christian Hampel
Journal:  BMC Cancer       Date:  2010-05-06       Impact factor: 4.430

6.  Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.

Authors:  Yiyun Zhang; Huiping Zhao; Szilard Asztalos; Michael Chisamore; Yasmin Sitabkhan; Debra A Tonetti
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

7.  Protein kinases C isozymes are differentially expressed in human breast carcinomas.

Authors:  Shadan Ali; Sana Al-Sukhun; Bassel F El-Rayes; Fazlul H Sarkar; Lance K Heilbrun; Philip A Philip
Journal:  Life Sci       Date:  2009-03-24       Impact factor: 5.037

8.  Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.

Authors:  D A Tonetti; M J Chisamore; W Grdina; H Schurz; V C Jordan
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  Protein kinase C Beta in the tumor microenvironment promotes mammary tumorigenesis.

Authors:  Julie A Wallace; Jason R Pitarresi; Nandini Sharma; Marilly Palettas; Maria C Cuitiño; Steven T Sizemore; Lianbo Yu; Allen Sanderlin; Thomas J Rosol; Kamal D Mehta; Gina M Sizemore; Michael C Ostrowski
Journal:  Front Oncol       Date:  2014-04-23       Impact factor: 6.244

10.  Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.

Authors:  Jason K Cullen; Glen M Boyle; Pei-Yi Yap; Stefan Elmlinger; Jacinta L Simmons; Natasa Broit; Jenny Johns; Blake Ferguson; Lidia A Maslovskaya; Andrei I Savchenko; Paul Malek Mirzayans; Achim Porzelle; Paul V Bernhardt; Victoria A Gordon; Paul W Reddell; Alberto Pagani; Giovanni Appendino; Peter G Parsons; Craig M Williams
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.